UNSPSC 51342700: Antiviral peptides

Antiviral drugs made from members of the class of compounds composed of amino acids joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures.

UNSPSC 51342700 Antiviral peptides is a Class code, but the recent state and local opportunities tagged under it do not align with antiviral peptides as a product category. Instead, the code shows solicitation activity for naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs. State and local governments are using this code to procure emergency medical supplies, pharmacy benefit management services, and pharmaceutical distribution arrangements rather than peptide-based antivirals. The issuing bodies include county health departments, state health and human services commissions, municipal fire departments, and multistate cooperative purchasing alliances — a mix of frontline health care and emergency services agencies alongside centralized procurement vehicles serving multiple jurisdictions.

Activity is concentrated in Florida and Minnesota with Texas state-level engagement. Seminole County, Florida issued an IFB (60459723LAS) in June 2026 for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The City of Tampa's Purchasing Department issued an IFB (26P00145) in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a designation as a sheltered market for certified Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs — a market intelligence phase preceding formal contracting. The mismatch between the code's nominal scope and the actual procurement activity suggests the code assignment may reflect administrative tagging rather than substantive alignment with antiviral peptide products.